Page 56 - GlaxoSmithKline Pharmaceuticals AR 2012

52
Notes to the Financial Statements for the year ended 31st December, 2012 — continued
37 Employee benefits expenses in Note 35 include amounts subject to approval of members in ensuing Annual General Meeting -
Rs. 80.18 lakhs (Previous year - Nil).
38 The recurring expenditure on research and development charged off to revenue amounts to Rs. 2,40.34 lakhs (Previous year -
Rs. 3,82.79 lakhs).
39 Miscellaneous expenses in Note 36 include loss on foreign currency transactions (net) Rs. 3,14.72 lakhs (Previous year -
Rs. 6,05.80 lakhs).
40 “Reimbursement of expenses (net)” in Note 36 are amounts recovered from GlaxoSmithKline Asia Private Limited Rs. 3,25.98 lakhs
(Previous year - Rs. 3,00.37 lakhs), from subsidiary company Rs. 3,20.63 lakhs (Previous year - Rs. 5,31.59 lakhs), from Stiefel India
Private Limited Rs. 15.53 lakhs (Previous year - Rs. 14.50 lakhs), from GlaxoSmithKline Pte Limited Rs. 62.04 lakhs (Previous year -
Rs. 59.86 lakhs), from GlaxoSmithKline Service Unlimited Rs. 80.68 lakhs (Previous year - 23.95 lakhs) and paid to GlaxoSmithKline
Consumer Healthcare Limited Rs. 11,00.66 lakhs (Previous year - Rs. 10,04.34 lakhs) towards the value of costs apportioned,
in accordance with the agreements on allocation of expenses with the companies.
Rupees
in lakhs
Previous year
Rupees
in lakhs
41 Exceptional items:
Expenses on rationalisation initiatives mainly relating to a manufacturing site
– Voluntary retirement scheme .. .. .. .. .. .. .. (98,05.56) (9,12.62)
– Others .. .. .. .. .. .. .. .. .. .. (36,64.18) (14,27.90)
Provisions for Government’s demand in respect of Betamethasone bulk drugs and formulations — (300,54.82)
Actuarial gain/(loss) on employee benefits .. .. .. .. .. .. (13,51.96) 1,41.20
(148,21.70) (322,54.14)
42 C.I.F. value of imports in respect of:
Raw and packing materials .. .. .. .. .. .. .. .. 60,24.91 70,61.09
Traded goods .. .. .. .. .. .. .. .. .. 142,33.77 108,87.38
Components and spare parts for Machinery .. .. .. .. .. .. — 15.21
Capital Goods .. .. .. .. .. .. .. .. .. 12,64.83 7,64.71
215,23.51 187,28.39
43 Dividend remitted in foreign currency: 2011 2010
On 3,04,85,250 equity shares to Glaxo Group Limited, U.K. .. .. .. .. 137,18.36 121,94.10
On 58,80,000 equity shares to Eskaylab Limited, U.K. .. .. .. .. 26,46.00 23,52.00
On 33,60,000 equity shares to Burroughs Wellcome International Limited, U.K. .. 15,12.00 13,44.00
On 31,92,238 equity shares to Castleton Investment Limited, Mauritius .. .. 14,36.51 12,76.90
44 Expenditure in foreign currency on account of:
– Travelling .. .. .. .. .. .. .. .. .. .. 1,22.14 75.78
– Selling commission on exports .. .. .. .. .. .. .. — —
– Royalty .. .. .. .. .. .. .. .. .. .. 9.75 7.98
– Others .. .. .. .. .. .. .. .. .. .. 4,45.74 4,39.03
5,77.63 5,22.79
45 Earnings in foreign exchange on account of:
F.O.B. value of exports including through merchant exporters .. .. .. .. 19,59.29 36,50.64
Recovery of expenses .. .. .. .. .. .. .. .. 46.43 32.30
Clinical research and data management .. .. .. .. .. .. 45,41.18 40,96.17
Research and development .. .. .. .. .. .. .. .. — 66.25
Others .. .. .. .. .. .. .. .. .. .. 6,04.67 1,41.87
71,51.57 79,87.23